Blinding isn’t just about the patients - It’s about the therapy providers as well. We would like to think they’d provide the same treatment regardless of what the patient received but over-eager researchers tend to get more excited about the active group and provide them more attention and enthusiasm.
Niacin isn’t a great placebo these days because it’s not the 70s any more and people going into these studies will probably Google what to expect from the drug. Also Niacin is short acting and makes people itchy and uncomfortable, so it’s not really compatible with therapy.
Niacin isn’t a great placebo these days because it’s not the 70s any more and people going into these studies will probably Google what to expect from the drug. Also Niacin is short acting and makes people itchy and uncomfortable, so it’s not really compatible with therapy.